ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Buy” by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus recommendation of “Buy” from the four research firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $80.00.

A number of research firms have weighed in on ANIP. Truist Financial upped their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd.

Insider Activity at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,787 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.55, for a total value of $510,437.85. Following the completion of the sale, the chief financial officer now owns 177,712 shares of the company’s stock, valued at approximately $11,649,021.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Muthusamy Shanmugam sold 10,093 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $65.35, for a total transaction of $659,577.55. Following the sale, the chief operating officer now directly owns 872,527 shares of the company’s stock, valued at approximately $57,019,639.45. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,787 shares of ANI Pharmaceuticals stock in a transaction on Monday, March 11th. The stock was sold at an average price of $65.55, for a total transaction of $510,437.85. Following the completion of the transaction, the chief financial officer now directly owns 177,712 shares of the company’s stock, valued at approximately $11,649,021.60. The disclosure for this sale can be found here. Insiders have sold 176,803 shares of company stock valued at $11,695,866 over the last ninety days. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its position in ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 248 shares during the period. BluePath Capital Management LLC bought a new stake in ANI Pharmaceuticals in the third quarter valued at $34,000. Pacer Advisors Inc. acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at $41,000. AJOVista LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $58,000. Finally, SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter worth about $106,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANIP opened at $65.62 on Friday. The company has a 50 day moving average of $66.96 and a two-hundred day moving average of $59.36. ANI Pharmaceuticals has a 52-week low of $38.91 and a 52-week high of $70.81. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.38 billion, a P/E ratio of 78.12 and a beta of 0.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The firm had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. On average, analysts expect that ANI Pharmaceuticals will post 3.55 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.